Human Aldo-Keto Reductase Family 1 Member C2 (AKR1C2) Protein
Por favor contáctenos para obtener información detallada sobre el precio y disponibilidad.
Description
Human Aldo-Keto Reductase 1C2 Protein is a recombinant protein from Human produced in E. coli. Recombinant Human Aldo-Keto Reductase Family 1 Member C2 is produced by our E.coli expression system and the target gene encoding Met1-Tyr323 is expressed.
Documents del producto
Product specifications
| Category | Proteins and Peptides |
| Immunogen Target | Aldo-Keto Reductase 1C2 |
| Host | E. coli |
| Origin | Human |
| Observed MW | Molecular Weight: 36.7 kDa Sequence Fragment: Met1-Tyr323 Validity: The validity for this protein is 6 months. |
| Expression | Recombinant |
| Purity | > 90% (SDS-PAGE) |
| Size 1 | 10 µg |
| Size 2 | 50 µg |
| Form | |
| Tested Applications | SDS-PAGE |
| Buffer | 20mM TrisHCl, 100mM NaCl, 1mM DTT, pH 8.0. |
| Availability | Shipped within 5-15 working days. |
| Storage | Aliquot and store at < -20 °C. Avoid repeated freeze/thaw cycles. |
| Dry Ice | No |
| UniProt ID | P52895 |
| Alias | AKR1C2,DDH2 |
| Background | Protein AKR1C2 |
| Status | RUO |
| Note | This product is for research use only. Not for human consumption, cosmetic, therapeutic or diagnostic use. |
Descripción
AKR1C2, known as 3α-hydroxysteroid dehydrogenase, catalyzes the reduction of 5α-dihydrotestosterone (DHT) to 3α-androstanediol, thereby inactivating this potent androgen. AKR1C2 is a key regulator of androgen and neurosteroid metabolism, playing a crucial role in modulating androgen signaling in tissues such as the prostate, brain, and liver. Dysregulation of AKR1C2 is associated with androgen-driven diseases, including prostate cancer, where its activity can suppress DHT levels and attenuate androgen receptor signaling. AKR1C2 also metabolizes progesterone and other steroid intermediates, linking it to reproductive and neuroendocrine functions. Its role in neurosteroid metabolism influences processes like synaptic inhibition, neuroprotection, and stress responses in the brain. Overexpression of AKR1C2 has been reported in cancers and drug-resistant tumors, where it contributes to detoxifying reactive carbonyl species and reducing chemotherapeutic efficacy. As a result, AKR1C2 is considered a therapeutic target for prostate cancer and neurodegenerative disorders.
Related Products
AKR1C2 antibody
This gene encodes a member of the aldo/keto reductase superfamily, which consists of more than 40 known enzymes and proteins. These enzymes catalyze the conversion of aldehydes and ketones to their corresponding alcohols using NADH and/or NADPH as cofactors. The enzymes display overlapping but distinct substrate specificity. This enzyme binds bile acid with high affinity, and shows minimal 3-alpha-hydroxysteroid dehydrogenase activity. This gene shares high sequence identity with three other gene members and is clustered with those three genes at chromosome 10p15-p14. Three transcript variants encoding two different isoforms have been found for this gene.
Ver Producto
Recombinant Human AKR1C2
Ver Producto